Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy

Siano, Marco; Infante, Gabriele; Resteghini, Carlo; Cau, Maria Chiara; Alfieri, Salvatore; Bergamini, Cristiana; Granata, Roberta; Miceli, Rosalba; Locati, Laura D.; Licitra, Lisa; Bossi, Paolo

doi:10.1016/j.oraloncology.2017.04.002

Cited by 17 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the event of an advanced HNSCC, a multidisciplinary approach, including surgery, chemotherapy and radiotherapy (RT), is required [ 12 , 13 ]. Patients who experience cancer progression within 3 months after platinum-based chemotherapy of primary or recurrent disease have a median survival rate of 6 months or less [ 14 ]. In recent decades, the survival rate has not been significantly increased.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy

Puntigam

Jeske

Götz

et al. 2020

IJMS

View full text Add to dashboard Cite

Endogenous control mechanisms, including immune checkpoints and immunosuppressive cells, are exploited in the process of tumorigenesis to weaken the anti-tumor immune response. Cancer treatment by chemotherapy or immune checkpoint inhibition can lead to changes of checkpoint expression, which influences therapy success. Peripheral blood lymphocytes (PBL) and tumor-infiltrating lymphocytes (TIL) were isolated from head and neck squamous cell carcinoma (HNSCC) patients (n = 23) and compared to healthy donors (n = 23). Immune checkpoint expression (programmed cell death ligand 1 (PD-1), tumor necrosis factor receptor (TNFR)-related (GITR), CD137, tumor necrosis factor receptor superfamily member 4 (TNFRSF4) (OX40), t-cell immunoglobulin and mucin-domain containing-3 (TIM3), B- and T-lymphocyte attenuator (BTLA), lymphocyte-activation gene 3 (LAG3)) was determined on immune cells by flow cytometry. PD-L1 expression was detected on tumor tissue by immunohistochemistry. Immune cells were treated with immuno- and chemotherapeutics to investigate treatment-specific change in immune checkpoint expression, in vitro. Specific changes of immune checkpoint expression were identified on PBL and TIL of HNSCC patients compared to healthy donors. Various chemotherapeutics acted differently on the expression of immune checkpoints. Changes of checkpoint expression were significantly less pronounced on regulatory T cells compared to other lymphocyte populations. Nivolumab treatment significantly reduced the receptor PD-1 on all analyzed T cell populations, in vitro. The specific immune checkpoint expression patterns in HNSCC patients and the investigated effects of immunomodulatory agents may improve the development and efficacy of targeted immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy

Puntigam

Jeske

Götz

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…At that time, patients were treated with different modalities, retrieving some benefit, but only if they were able to receive further lines of therapy. 11 This could be even more important with new therapies showing improved survival in the second-line setting.…”

Section: Discussionmentioning

confidence: 99%

Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer

Siano

Espeli

Joerger

2018

Tumori

Self Cite

View full text Add to dashboard Cite

Background: Delay of systemic treatment in recurrent/metastatic head and neck squamous cell cancer (r/mHNSCC) has never been assessed. Whether time span to start systemic treatment affects survival and whether referral to a medical oncologist is important has not been explored. Methods: We analyzed our head and neck database to assess the prognostic impact of time between diagnosis of r/mHNSCC and start of systemic treatment (time to treatment [TTT]). Secondarily, we assessed the prognostic impact of time to referral to a medical oncologist (referral time). For this purpose, we used pairwise correlation analysis and multivariate Cox regression analysis as statistical tests. Results: A total of 110 patients with r/mHNSCC were evaluable for analysis. TTT correlated significantly with OS from r/mHNSCC diagnosis ( R = 0.43, p < 0.0001). A nonsignificant, positive correlation was found between referral time and OS ( R = 0.17, p = 0.10). Conclusions: Results of this retrospective analysis suggest that longer TTT is not associated with worse prognosis. Referral time seems not to have an impact on prognosis.

show abstract

“…Over the past decade, retrospective and observational studies have consistently confirmed the benefits of the EXTREME regimen in patients with first-line recurrent and/or metastatic HNSCC [9,10]. There is evidence that maintenance therapy until disease progression with cetuximab as a single agent following the EXTREME regimen is also well tolerated with a good compliance (relative dose intensity = 82%) [11].…”

Section: Introductionmentioning

confidence: 96%

Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer

et al. 2018

View full text Add to dashboard Cite

Objectives: This study evaluates maintenance cetuximab administered every 2 weeks (q2w) after chemotherapy plus cetuximab as first-line treatment in a series of patients with head and neck squamous cell cancer and compares the results with those obtained in a historical control group of patients receiving weekly cetuximab. Methods: After chemotherapy plus cetuximab as first-line treatment, in Group A, 36 patients enrolled from October 2016 to November 2017, received biweekly cetuximab, administered at 500 mg/m². Group B was a control group of patients treated at our institution from August 2015 to September 2016 and received weekly infusion of cetuximab at 250 mg/m². Results: Confirmed overall response rates were, respectively, 19% for Group A and 17% for Group B according to intention-to-treat analysis. During the maintenance treatment, median progression-free survival (PFS) and median overall survival (OS) were similar for both groups (PFS, 4.8 and 4.4 months; OS, 9.0 and 7.9 months; in Groups A and B, respectively). The most common adverse events among treated subjects included fatigue, rash, and hypomagnesemia. Conclusion: Maintenance therapy with simplified biweekly cetuximab is a convenient, effective, and well-tolerated regimen in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

show abstract

Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy

Cited by 17 publications

References 12 publications

Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy

Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy

Time to systemic treatment and prognosis in patients with recurrent and metastatic head and neck squamous cell cancer

Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer

Contact Info

Product

Resources

About